COMMUNIQUÉS West-GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
20/05/2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
Aveanna to Participate at the UBS Healthcare Services Cape Cod Summit and Jefferies Global Healthcare Conference
20/05/2024
ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the UBS Healthcare Services Cape Cod Summit in Chatham, MA on [...]
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
20/05/2024
New production process will be developed based on Pluri’s proprietary 3D cell expansion technology Human breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adults [...]
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
20/05/2024
Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero [...]
At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
20/05/2024
Arecor Therapeutics plc (“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES AT278 [...]
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
20/05/2024
Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO ® in China, Hong Kong, Macau, [...]
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
20/05/2024
FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing [...]
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Delisting Decision from the Nasdaq Hearings Panel
20/05/2024
SHENZHEN, China, May 20, 2024 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced [...]
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
20/05/2024
BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex ® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use [...]
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
20/05/2024
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and [...]
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
20/05/2024
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion [...]
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
20/05/2024
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
20/05/2024
LA JOLLA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Pharming Group to participate in May investor conference
20/05/2024
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of [...]
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
20/05/2024
ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to [...]
Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
20/05/2024
GAITHERSBURG, MD, May 20, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“ Amplexd ” or the “ Company ”), a clinical stage patient-scientist-led biotech company specializing in accessible treatments for human [...]
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
20/05/2024
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of [...]
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
19/05/2024
WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Intercept Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on ALP and Metabolic Outcomes After Six Months of Treatment at Digestive Disease Week® 2024
18/05/2024
Results from a Phase 2 study show combination of OCA 5-10mg and bezafibrate 400mg induced the greatest percent change from baseline in ALP at Month 6 OCA and bezafibrate combination therapy has acceptable metabolic [...]

Pages